FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2003075460> ?p ?o ?g. }

• W2003075460 endingPage "253" @default.
• W2003075460 startingPage "243" @default.
• W2003075460 abstract "Raf-1 protein serine/threonine kinase plays an important role in cell proliferation and cell survival. We have previously described a novel cationic liposome-entrapped formulation of raf antisense oligodeoxyribonucleotide (LErafAON) and its use as a radiosensitizer. The aim of this study was to examine the effect of combination of LErafAON and a chemotherapeutic agent on growth of human prostate (PC-3) and pancreatic tumor xenografts in athymic mice (Aspc-1 and Colo 357). In PC-3 tumor-bearing mice, administration of a combination of LErafAON (i.v., 25 mg/kg/dose, ×10/16) and cisplatin (i.v., 11.0 mg/kg/dose, ×3), epirubicin (EPI) (i.v., 9.0 mg/kg/dose, ×3) or mitoxantrone (MTO) (i.v., 2.5 mg/kg/dose, ×3) led to enhanced tumor growth inhibition as compared with single agents (LErafAON+cisplatin versus cisplatin, p<0.0002, n=8; LErafAON+EPI versus EPI, p<0.0001, n=6; LErafAON+MTO versus MTO, p<0.05, n=5). In prostate or pancreatic tumor-bearing mice, combination of LErafAON (i.v., 25 mg/kg/dose, ×10/13) with docetaxel (Taxotere) (i.v., 5, 7.5 or 10 mg/kg/dose, ×2/4) led to tumor regression or enhanced growth inhibition as compared with single agents (PC-3: LErafAON+Taxotere versus Taxotere, p<0.02, n=7; Aspc-1: LErafAON+Taxotere versus Taxotere, p<0.03, n=5; Colo 357: LErafAON+Taxotere versus Taxotere, p<0.04, n=7). Combination of LErafAON (i.v., 25 mg/kg/dose, ×10/13) with gemcitabine (i.v., 75 mg/kg/dose, ×4/6) also caused a significant tumor growth inhibition in the two pancreatic carcinoma models studied (Aspc-1: LErafAON+gemcitabine versus gemcitabine, p<0.0001, n=7; Colo 357: LErafAON+gemcitabine versus gemcitabine, p<0.002, n =5). LErafAON treatment (i.v., 25 mg/kg/dose, ×10) caused inhibition of Raf-1 protein expression in these tumor tissues (around 25–60%, n=4–7). Interestingly, Taxotere treatment per se also led to decreased steady state level of Raf-1 protein in PC-3 and Aspc-1 tumor tissues (i.v., 10 mg/kg/dose, ×1 or 7.5 mg/kg/dose, ×2; around 25–80%, n=2/6). Present studies demonstrate enhanced tumor growth inhibition or regression in response to a combination of a chemotherapeutic drug and LErafAON. These data provide a proof-of-principle for the clinical use of LErafAON in combination with chemotherapy for cancer treatment." @default.
• W2003075460 created "2016-06-24" @default.
• W2003075460 creator A5030299515 @default.
• W2003075460 creator A5052787538 @default.
• W2003075460 creator A5069729806 @default.
• W2003075460 creator A5071648735 @default.
• W2003075460 creator A5072559983 @default.
• W2003075460 creator A5080775024 @default.
• W2003075460 creator A5081134776 @default.
• W2003075460 date "2004-03-01" @default.
• W2003075460 modified "2023-10-14" @default.
• W2003075460 title "Combination with liposome-entrapped, ends-modified raf antisense oligonucleotide (LErafAON) improves the anti-tumor efficacies of cisplatin, epirubicin, mitoxantrone, docetaxel and gemcitabine" @default.
• W2003075460 cites W148617260 @default.
• W2003075460 cites W1555549645 @default.
• W2003075460 cites W1598432003 @default.
• W2003075460 cites W1638912731 @default.
• W2003075460 cites W1967861082 @default.
• W2003075460 cites W1968142651 @default.
• W2003075460 cites W1968517488 @default.
• W2003075460 cites W1971869045 @default.
• W2003075460 cites W1973513609 @default.
• W2003075460 cites W1983603860 @default.
• W2003075460 cites W1989052124 @default.
• W2003075460 cites W1993491727 @default.
• W2003075460 cites W1999995381 @default.
• W2003075460 cites W2005681966 @default.
• W2003075460 cites W2006375405 @default.
• W2003075460 cites W2008046168 @default.
• W2003075460 cites W2008872627 @default.
• W2003075460 cites W2012939857 @default.
• W2003075460 cites W2021133538 @default.
• W2003075460 cites W2030889696 @default.
• W2003075460 cites W2037758170 @default.
• W2003075460 cites W2040799311 @default.
• W2003075460 cites W2041687747 @default.
• W2003075460 cites W2043478531 @default.
• W2003075460 cites W2046508793 @default.
• W2003075460 cites W2050085273 @default.
• W2003075460 cites W2056605140 @default.
• W2003075460 cites W2057126981 @default.
• W2003075460 cites W2062921699 @default.
• W2003075460 cites W2064141793 @default.
• W2003075460 cites W2068629038 @default.
• W2003075460 cites W2069158176 @default.
• W2003075460 cites W2081419234 @default.
• W2003075460 cites W2081969062 @default.
• W2003075460 cites W2088712533 @default.
• W2003075460 cites W2092930138 @default.
• W2003075460 cites W2098468369 @default.
• W2003075460 cites W2112808044 @default.
• W2003075460 cites W2114207292 @default.
• W2003075460 cites W2121627701 @default.
• W2003075460 cites W2133396287 @default.
• W2003075460 cites W2133408651 @default.
• W2003075460 cites W2135791859 @default.
• W2003075460 cites W2137715268 @default.
• W2003075460 cites W2153534791 @default.
• W2003075460 cites W2157721629 @default.
• W2003075460 cites W2161779132 @default.
• W2003075460 cites W2164034599 @default.
• W2003075460 cites W2173081403 @default.
• W2003075460 cites W2183542972 @default.
• W2003075460 cites W2319257648 @default.
• W2003075460 cites W2320164363 @default.
• W2003075460 cites W2328224885 @default.
• W2003075460 cites W2623930462 @default.
• W2003075460 cites W4250448824 @default.
• W2003075460 cites W7247080 @default.
• W2003075460 doi "https://doi.org/10.1097/00001813-200403000-00009" @default.
• W2003075460 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/15014358" @default.
• W2003075460 hasPublicationYear "2004" @default.
• W2003075460 type Work @default.
• W2003075460 sameAs 2003075460 @default.
• W2003075460 citedByCount "25" @default.
• W2003075460 countsByYear W20030754602013 @default.
• W2003075460 countsByYear W20030754602014 @default.
• W2003075460 countsByYear W20030754602015 @default.
• W2003075460 countsByYear W20030754602016 @default.
• W2003075460 countsByYear W20030754602019 @default.
• W2003075460 countsByYear W20030754602022 @default.
• W2003075460 crossrefType "journal-article" @default.
• W2003075460 hasAuthorship W2003075460A5030299515 @default.
• W2003075460 hasAuthorship W2003075460A5052787538 @default.
• W2003075460 hasAuthorship W2003075460A5069729806 @default.
• W2003075460 hasAuthorship W2003075460A5071648735 @default.
• W2003075460 hasAuthorship W2003075460A5072559983 @default.
• W2003075460 hasAuthorship W2003075460A5080775024 @default.
• W2003075460 hasAuthorship W2003075460A5081134776 @default.
• W2003075460 hasConcept C126322002 @default.
• W2003075460 hasConcept C185592680 @default.
• W2003075460 hasConcept C190283241 @default.
• W2003075460 hasConcept C2776428644 @default.
• W2003075460 hasConcept C2776694085 @default.
• W2003075460 hasConcept C2776755627 @default.
• W2003075460 hasConcept C2777844706 @default.
• W2003075460 hasConcept C2778119113 @default.
• W2003075460 hasConcept C2778239845 @default.
• W2003075460 hasConcept C2779707156 @default.

• next